Search alternatives:
significant substantial » significant potential (Expand Search), significant spatial (Expand Search)
substantial decrease » substantial increase (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
Showing 1 - 20 results of 5,553 for search '(( significant clinical decrease ) OR ( significant substantial decrease ))', query time: 0.39s Refine Results
  1. 1
    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

    Published 2025
    “…The substantial and differential decrease in testosterone and SHBG levels does not explain our previous finding of no detected decrease in risky sexual behavior or sexual function for DMPA-IM or NET-EN users from D0 to 25W. …”
    Save to List
    Saved in:
  2. 2
    Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC.

    Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Degeneration Saline group presented with significant decreased final weight in relation to other groups.

    Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 10
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 11
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 12
    Analysis of Significantly Different Bacteria.

    Analysis of Significantly Different Bacteria. by Xu Jia (187142)

    Published 2025
    Save to List
    Saved in:
  13. 13
    Analysis of Significantly Different ARGs and Resistance Mechanisms.

    Analysis of Significantly Different ARGs and Resistance Mechanisms. by Xu Jia (187142)

    Published 2025
    Save to List
    Saved in:
  14. 14
    Age-standardized rates of PUD in 204 countries globally by SDI in 2021.

    Age-standardized rates of PUD in 204 countries globally by SDI in 2021. by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Age-standardized rates of PUD globally and for 21 GBD regions by SDI, 1990–2021.

    Age-standardized rates of PUD globally and for 21 GBD regions by SDI, 1990–2021. by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    The top four countries or territories with the lowest ASRs of PUD in 2021.

    The top four countries or territories with the lowest ASRs of PUD in 2021. by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Trends in the all-age numbers and age-standardized incidence, prevalence, mortality and DALYs rates of PUD by sex from 1990 to 2021.

    Trends in the all-age numbers and age-standardized incidence, prevalence, mortality and DALYs rates of PUD by sex from 1990 to 2021. by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Numbers and age-standardized incidence, prevalence, deaths and DALYs rates of peptic ulcer disease in 2021.

    Numbers and age-standardized incidence, prevalence, deaths and DALYs rates of peptic ulcer disease in 2021. by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Proportion of PUD DALYs and deaths attributable to smoking by gender, SDI quintile, and GBD region in 1990 and 2021.

    Proportion of PUD DALYs and deaths attributable to smoking by gender, SDI quintile, and GBD region in 1990 and 2021. by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    S1 File - Global burden and risk factors of peptic ulcer disease between 1990 and 2021: An analysis from the global burden of disease study 2021

    S1 File - Global burden and risk factors of peptic ulcer disease between 1990 and 2021: An analysis from the global burden of disease study 2021 by Wende Hao (10315597)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: